Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
AIDS (London, England)
|
April 7, 2026
Longitudinal challenges faced by perinatally-infected young people living with HIV in Kenya during the COVID-19 pandemic
Manjot Singh, Winstone Nyandiko, Allison DeLong, et al.
The New England Journal of Medicine
|
September 21, 2023
Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19
David R Boulware, Christopher J Lindsell, Thomas G Stewart, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 27, 2022
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Matthew W McCarthy, Susanna Naggie, David R Boulware, et al.
JAMA
|
January 12, 2023
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Matthew W McCarthy, Susanna Naggie, David R Boulware, et al.
JAMA
|
October 21, 2022
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Susanna Naggie, David R Boulware, Christopher J Lindsell, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 23, 2022
Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial
Susanna Naggie, David R Boulware, Christopher J Lindsell, et al.
JAMA
|
February 22, 2023
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial
Susanna Naggie, David R Boulware, Christopher J Lindsell, et al.
JAMA
|
November 17, 2023
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial
Thomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
JAMA Network Open
|
October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
AIDS (London, England)
|
April 7, 2026
Longitudinal challenges faced by perinatally-infected young people living with HIV in Kenya during the COVID-19 pandemic
Manjot Singh, Winstone Nyandiko, Allison DeLong, et al.
The New England Journal of Medicine
|
September 21, 2023
Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19
David R Boulware, Christopher J Lindsell, Thomas G Stewart, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 27, 2022
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Matthew W McCarthy, Susanna Naggie, David R Boulware, et al.
JAMA
|
January 12, 2023
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Matthew W McCarthy, Susanna Naggie, David R Boulware, et al.
JAMA
|
October 21, 2022
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Susanna Naggie, David R Boulware, Christopher J Lindsell, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 23, 2022
Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial
Susanna Naggie, David R Boulware, Christopher J Lindsell, et al.
JAMA
|
February 22, 2023
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial
Susanna Naggie, David R Boulware, Christopher J Lindsell, et al.
JAMA
|
November 17, 2023
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial
Thomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
JAMA Network Open
|
October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
Page
of 5